0000000001092363

AUTHOR

Tack C. J.

showing 1 related works from this author

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.

2019

BACKGROUND Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. METHODS We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular risk (age of ≥50 years with established cardiovascular or chronic kidney disease, or age of ≥60 years with cardiovascular risk factors only). The primary outcome in a time-to-event analysis was the first occurrence of a major adverse cardiovascular event (death fro…

OralMaleRiskGlucagon-Like PeptideGlycated Hemoglobin AGlucagon-Like PeptidesAdministration OralGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaAll institutes and research themes of the Radboud University Medical CenterDouble-Blind MethodCardiovascular DiseaseDiabetes MellitusHumansHypoglycemic AgentsSettore MED/49 - Scienze Tecniche Dietetiche ApplicateAgedGlycated HemoglobinHypoglycemic AgentMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]General MedicineMiddle AgedAdministration Oral; Aged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Male; Middle Aged; RiskDiabetes Mellitus Type 2Cardiovascular DiseasesAdministrationFemaleType 2Human
researchProduct